Timedora

The Role of Pharmacotherapy in Acute Coronary Syndromes

An overview of what ACS medicines are meant to do, how they fit alongside procedures, and what guides their selection and timing.

Why Medicines Are Used in ACS

What pharmacotherapy is for

Acute coronary syndromes (ACS)—ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina—usually involve a disrupted coronary plaque, platelet activation, and a forming thrombus. Medicines address several parts of this problem: antithrombotic drugs limit clot formation; other treatments can lower the heart’s oxygen demand, relieve ischemic symptoms, and help prevent complications.

Medicines do not replace timely reperfusion or other indicated procedures. Their choice and timing must fit the ACS type and treatment plan, as well as the patient’s hemodynamic status, bleeding risk, renal function, and contraindications. In short, ACS pharmacotherapy is tailored supportive treatment alongside—not instead of—procedural care.